Aarti Drugs enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


3,423	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
7.3	7.3	4.6	6.7	9.0
0.4	0.4	0.3	0.4	0.2
575	575	612	562	607
3,991	—	—	—	—
568	568	608	556	598
₹437.23	—	—	—	—

2,124	2,124	1,982	1,844	1,799
27.1%	27.1%	30.9%	30.5%	33.7%
0.14×	—	—	—	—

1.49×	—	—	—	—
11.97×	—	—	—	—
15.20×	—	—	—	—
49.75×	—	—	—	—
2,678	2,565	2,387	2,529	2,716
333	309	287	316	306
263	242	231	265	255
—	254	245	359	134
80.2	80.2	67.4	133	−30.5
—	77.8	60.5	124	−39.8
—	173	177	226	165

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AARTIDRUGS₹375.00

Aarti Drugs Ltd.

· Pharma & Health

₹ CrorePeersALIVUS AARTIPHARM ADVENZYMES AGARWALEYE AKUMS APLLTD CORONA HCGMcap ₹3,423 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	3,422.6
- Cash, Equiv & ST Investments	9.0	6.7	4.6	7.3	7.3
+ Minority Interest	0.2	0.4	0.3	0.4	0.4
+ Total Debt	606.5	562.4	612.2	574.8	574.8
Enterprise Value	—	—	—	—	3,990.6
Net Debt (memo)	597.6	555.7	607.7	567.6	567.6
EV per Share	—	—	—	—	437.23

Total Capital	1,799.2	1,844.4	1,981.6	2,124.1	2,124.1
Total Debt/Total Capital	33.71	30.49	30.90	27.06	27.06
Total Debt/EV	—	—	—	—	0.14

EV/Sales	—	—	—	—	1.49
EV/EBITDA	—	—	—	—	11.97
EV/EBIT	—	—	—	—	15.20
EV/Free Cash Flow	—	—	—	—	49.75
Reference Items — Trailing FY Values
Sales	2,716.1	2,528.6	2,387.0	2,565.3	2,677.6
EBITDA	305.6	316.5	287.1	309.2	333.3
EBIT	255.3	265.0	231.3	242.2	262.6
Operating Cash Flow	134.2	358.9	244.6	253.5	—
Free Cash Flow	-30.5	132.6	67.4	80.2	80.2
FCFF (free cash flow to the firm)	-39.8	124.1	60.5	77.8	—
Capital Expenditure	164.7	226.3	177.2	173.3	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.